{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-24-018140","form_type":"8-K","ticker":"DMAC","cik":"0001401040","company_name":"DiaMedica Therapeutics Inc.","filed_at":"2024-05-23T23:59:59+00:00","discovered_at":"2026-05-14T18:03:18.246845+00:00","generated_at":"2026-06-01T09:08:01.766283+00:00","sec_items":["5.02","5.07","9.01"],"event_type":"other","sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"confidence":"high","headline":"DiaMedica shareholders approve 3M share increase to 2019 Omnibus Incentive Plan","bullets":["Shareholders approved amendment to increase shares available under 2019 Omnibus Incentive Plan by 3,000,000 shares.","All seven director nominees elected with >13.5M votes each; broker non-votes of ~11.77M.","Baker Tilly US, LLP appointed as independent auditor for FY2024 with 24.97M votes for.","Advisory vote on executive compensation passed (13.18M for); shareholders prefer one-year say-on-pay frequency.","67.9% of outstanding shares (25.77M of 37.96M) voted at the annual meeting."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-24-018140","json":"https://secwatch.observer/filing/0001437749-24-018140.json","markdown":"https://secwatch.observer/filing/0001437749-24-018140.md","text":"https://secwatch.observer/filing/0001437749-24-018140.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1401040/000143774924018140/0001437749-24-018140-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1401040/000143774924018140/dmtp20240523_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-01T09:08:01.766283+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}